AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 36468650
Drug: CBTp (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBTp (Cognitive Behavioral Therapy for parasomnias)
Trial: 32449002
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitors (PPI)
Trial: 37482940
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (OMT)
Trial: 32503556
Drug: Misoprostol (800mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (800mcg sublingual for treatment, 600mcg oral for prophylaxis)
Trial: 34878933
Drug: Laser Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser Therapy (LT) (808 nm, 100 mW, 40 sec/point, 4 J/point, intra/extraoral)
Trial: 33216013
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) group program PROTECT+, 4 sessions
Trial: 32627474
Drug: Zhibitai Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhibitai Capsules combined with statins
Trial: 38421679
Drug: Glucocorticoid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid injection
Trial: 39305035
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy
Trial: 35040506
Drug: Sirolimus (2-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (2-6 mg daily) for 48 weeks
Trial: 35882375
Drug: Oral carbohydrate
RxNorm normalized name: omega-3 carboxylic acids Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral carbohydrate (OC group) - 300 mL/bottle
Trial: 35882375
Drug: Oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo (OP group) - 300 mL distilled water
Trial: 34854808
Drug: Primary trabeculectomy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary trabeculectomy treatment - trabeculectomy augmented with mitomycin C
Trial: 34854808
Drug: Primary medical
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary medical treatment - escalating medical management with glaucoma eye drops
Trial: 33049730
Drug: 100% oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100% oxygen at 10 l/min until delivery
Trial: 34687435
Drug: Copaiba oil
RxNorm normalized name: COPAIBA OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Copaiba oil in silicone gel, applied twice a day for 84 days
Trial: 36160864
Drug: Acetazolamide (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (375 mg/d)
Trial: 33576219
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin gel (Curenext)
Trial: 33576219
Drug: Aloe Vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe Vera gel (Aloe Vera 100% relief)
Trial: 37103493
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment as usual)
Trial: 35717193
Drug: Community-wide mass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-wide mass drug administration (MDA) with efficient duration of delivery (within ten days)
Trial: 35961520
Drug: Durvalumab (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (1500 mg intravenously) every 4 weeks for up to 24 months
Trial: 36042582
Drug: Low-frequency electric
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency electric pulse therapy (LFEPT) combined with tropisetron hydrochloride and dexamethasone hydrochloride
Trial: 36042582
Drug: Low-frequency electric
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency electric pulse therapy (LFEPT)
Trial: 35179082
Drug: Cognitive-Behavioural Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioural Therapy
Trial: 36410223
Drug: Bupropion 75
RxNorm normalized name: buPROPion 75 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupropion 75 mg twice daily for twelve weeks
Trial: 34188459
Drug: ICT-based multicomponent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICT-based multicomponent program applied twice per week, once per day for 12 weeks, 30 min per session
Trial: 36442484
Drug: Rezafungin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rezafungin (400 mg in week 1, followed by 200 mg weekly, for a total of two to four doses)
Trial: 36442484
Drug: Caspofungin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin (70 mg loading dose on day 1, followed by 50 mg daily)
Trial: 33838756
Drug: ChAdOx1 nCoV‐19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV‐19 vaccine (low dose)
Trial: 33838756
Drug: ChAdOx1 nCoV‐19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV‐19 vaccine (high dose)
Trial: 35584529
Drug: Mannitol solution
RxNorm normalized name: Mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mannitol solution
Trial: 35807836
Drug: C. rabens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. rabens extract capsule
Trial: 32352676
Drug: Contractubex gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contractubex gel applied 3 times a day for 9 months
Trial: 32352676
Drug: No regular
RxNorm normalized name: Aveeno Regular Bath
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No regular therapy (control group)
Trial: 32883514
Drug: High antimüllerian
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High antimüllerian hormone (AMH) levels in women with PCOS
Trial: 38497150
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment
Trial: 32272513
Drug: Ceramide-containing moisturizing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramide-containing moisturizing cream
Trial: 32835925
Drug: donepezil (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil (10 mg/day)
Trial: 36198467
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with usual daily activities
Trial: 33904792
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control (LA without laser output plus conventional treatment)
Trial: 35971655
Drug: galcanezumab-120 mg
RxNorm normalized name: galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: galcanezumab-120 mg
Trial: 35971655
Drug: galcanezumab-240 mg
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: galcanezumab-240 mg
Trial: 35971655
Drug: previous-galcanezumab-120 mg
RxNorm normalized name: galcanezumab-gnlm 120 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: previous-galcanezumab-120 mg
Trial: 35971655
Drug: previous-galcanezumab-240 mg
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: previous-galcanezumab-240 mg
Trial: 34851211
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (30 sessions of conventional treatment, 5 sessions per week)
Trial: 32909675
Drug: Anifrolumab (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anifrolumab (300 mg)
Trial: 35477563
Drug: Control lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control lozenges
Trial: 35417301
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of E. coli-produced HPV-16/18 bivalent vaccine
Trial: 32712034
Drug: Trigger Point
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigger Point Injections (TPIs) with 1% lidocaine
Trial: 32437568
Drug: Pedometer-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pedometer-based intervention with weekly step goals
Trial: 33158079
Drug: 85 g
RxNorm normalized name: UREA 17 g in 85 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 85 g of mango intake
Trial: 33380704
Drug: Candesartan (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (8 mg/day)
Trial: 32456272
Drug: Metformin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin + low-volume HIIT
Trial: 32456272
Drug: No Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Metformin + MICT
Trial: 32456272
Drug: No Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Metformin + high-volume HIIT
Trial: 32456272
Drug: No Metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Metformin + low-volume HIIT
Trial: 37418263
Drug: Erythropoietin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin treatment
Trial: 36376888
Drug: Venetoclax combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax combined with low dose cytarabine (VEN + LDAC)
Trial: 36376888
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care intensive chemotherapy (IC)
Trial: 36152639
Drug: Tirzepatide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirzepatide (5 mg, 10 mg, or 15 mg)
Trial: 32740593
Drug: Closed-incision negative-pressure
RxNorm normalized name: INCISED NOTOPTERYGIUM RHIZOME OR ROOT (NOTOPTERYGIUM FRANCHETII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-incision negative-pressure therapy
Trial: 34162822
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera mouthwash (20 ccs three times daily for 14 days)
Trial: 34162822
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (control group, 20 ccs three times daily for 14 days)
Trial: 32567941
Drug: Triticum vulgare
RxNorm normalized name: Triticum vulgare extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triticum vulgare (TV) spray, gluten-free, used twice daily after toothbrushing for 2 weeks
Trial: 33768368
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone Propionate Dry Powder Inhaler B-3.8 (500 μg)
Trial: 33462512
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (20 g per day)
Trial: 35413431
Drug: Interventional multimodal
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interventional multimodal sleep pathway including nursing‐directed nonpharmacologic measures, low‐dose zolpidem and melatonin at bedtime.
Trial: 34509197
Drug: 17 alpha-hydroxyprogesterone
RxNorm normalized name: 17 alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly once per week starting between 16 and 24 weeks of gestation until delivery, stillbirth, or reaching term (37 weeks)
Trial: 34509197
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered in the same manner as 17P
Trial: 32084053
Drug: Positively Smoke
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positively Smoke Free group therapy
Trial: 34921572
Drug: G-CEM ONE
RxNorm normalized name: CEM-Urea
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CEM ONE Adhesive Enhancing Primer (GCO-AEP) + GCO
Trial: 34540645
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% 20 mL (Control)
Trial: 34540645
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% 20 mL plus 4mg dexamethasone
Trial: 34540645
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% 20 mL plus 75 mcg dexmedetomidine
Trial: 32993775
Drug: ACAT group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACAT group (Cognitive-behavioral family therapy)
Trial: 34413169
Drug: TLR agonists
RxNorm normalized name: TLR-AD1
DrugBank: TLR-AD1 (DB18241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLR agonists only
Trial: 32711800
Drug: Emtricitabine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (200 mg) and tenofovir alafenamide (25 mg) daily
Trial: 32711800
Drug: Emtricitabine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) daily
Trial: 38864155
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of β-lactam antibiotics (piperacillin-tazobactam or meropenem)
Trial: 36424257
Drug: 4vHPV vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4vHPV vaccine
Trial: 34435513
Drug: 5 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg·kg‐1 placebo (PLA)
Trial: 34435513
Drug: 5 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg·kg‐1 caffeine (CAF)
Trial: 35238725
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) belimumab 10 mg/kg dose Q2W for three doses, then 10 mg/kg Q4W thereafter
Trial: 35238725
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) belimumab 400 mg dose QW for four doses, then 200 mg QW thereafter
Trial: 33291727
Drug: Static-sequential-permanent pictures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static-sequential-permanent pictures condition (n = 36)
Trial: 33291727
Drug: Static-sequential-transient pictures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static-sequential-transient pictures condition (n = 29)
Trial: 34280843
Drug: Interferon beta
RxNorm normalized name: Interferon beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta treatment
Trial: 38549128
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment (BMT)
Trial: 33823051
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication
Trial: 32143730
Drug: Capecitabine metronomic
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine metronomic chemotherapy
Trial: 32143730
Drug: Capecitabine conventional
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine conventional chemotherapy
Trial: 36354040
Drug: LY3437943 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3437943 3 mg
Trial: 36354040
Drug: LY3437943 3/6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3437943 3/6 mg
Trial: 36354040
Drug: LY3437943 3/6/9/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY3437943 3/6/9/12 mg
Trial: 34403548
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg oral midazolam
Trial: 34414678
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg once daily for 8 weeks
Trial: 35143622
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with bortezomib and DA‐EPOCH‐R for 6 cycles followed by observation in responding patients
Trial: 35143622
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with bortezomib and DA‐EPOCH‐R for 6 cycles followed by bortezomib maintenance in responding patients
Trial: 33788452
Drug: Governor Vessel
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Governor Vessel moxibustion therapy, applied once a week for 8 weeks.
Trial: 33788452
Drug: Atorvastatin calcium
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin calcium tablets (10 mg) once daily for 8 weeks (Control).
Trial: 33788452
Drug: Governor Vessel
RxNorm normalized name: acellular tissue engineered vessel Drug Implant [Symvess]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Governor Vessel moxibustion therapy (I) vs Atorvastatin (C) for CAS clinical effect.
Trial: 35483396
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy alone
Trial: 36480346
Drug: Mindfulness-based stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based stress reduction program combined with music therapy
Trial: 32931612
Drug: 400 units
RxNorm normalized name: alpha-D-galactosidase 400 units oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 units of vitamin E and 1,000 mg of vitamin C/day
Trial: 32640132
Drug: Nemolizumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nemolizumab (60 mg subcutaneously every 4 weeks)
Trial: 32800029
Drug: Daily inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily inhalation of budesonide 200 μg/day
Trial: 32800029
Drug: Intermittent inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent inhalation of budesonide 200 μg/day
Trial: 35133884
Drug: Blonanserin 16
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin 16 mg/day
Trial: 35133884
Drug: Blonanserin 8
RxNorm normalized name: Blonanserin
DrugBank: Blonanserin (DB09223)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Blonanserin 8 mg/day
Trial: 34067524
Drug: Magnesium supplement
RxNorm normalized name: Magnesium supplement
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium supplement (450 mg for men, 300 mg for women)
Trial: 34067524
Drug: Control (water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (water without magnesium supplement)
Trial: 33306418
Drug: Denosumab biosimilar
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Denosumab biosimilar (60 mg)
Trial: 35338860
Drug: Probiotic peanut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic peanut oral immunotherapy
Trial: 33798499
Drug: ChAdOx1 nCoV-19
RxNorm normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChAdOx1 nCoV-19 (AZD1222) vaccine
Trial: 36342343
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg p.o.)
Trial: 32410715
Drug: Video games
RxNorm normalized name: Encora AM Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video games not specifically designed to train cognition (CC) + endurance, strength, and music-movement coordination (EI)
Trial: 32410715
Drug: Video games
RxNorm normalized name: Encora AM Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video games not specifically designed to train cognition (CC) + stretching, toning, and relaxation (EC)
Trial: 32410715
Drug: Cognitive training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive training (CI or CC) + physical control activity (EC)
Trial: 32410715
Drug: Physical training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical training (EI or EC) + cognitive control activity (CC)
Trial: 32410715
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both control activities (CC + EC)
Trial: 33308122
Drug: Qingpeng ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingpeng ointment with routine medical treatment and rehabilitative care
Trial: 33308122
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment without Qingpeng ointment
Trial: 34407826
Drug: Talking therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talking therapy for depression
Trial: 32041669
Drug: Intravitreal dexamethasone
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal dexamethasone implant (700 μg)
Trial: 36225132
Drug: Edaravone oral
RxNorm normalized name: edaravone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone oral suspension administered orally
Trial: 33487257
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt (300 g/d)
Trial: 33861440
Drug: Metformin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (500 mg three times daily)
Trial: 32048274
Drug: Two consecutive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two consecutive doses of iv dexamethasone 24 mg
Trial: 36782325
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin